Objective
Due to the discontinuation of the related range of activities by the historical CMO, transfer of a portfolio of injectable emergency medicines to another CMO while transitioning to a new pre-filled syringe format
Outcome
- Selection and qualification of an alternate manufacturing site
- Transfer of three products from the portfolio, up to and including validation
- Project discontinuation after the decision of the sponsor to sell off this portfolio of products